Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2011-02-25

Clinical Trial Update: Safety and Efficacy Study of PEG-uricase in the Treatment of Hyperuricemic Patients With Symptomatic Gout [Phase 3]

View source ↗

Summary

Phase 3 trial update reporting safety and efficacy results for PEG-uricase (pegloticase) in hyperuricemic patients with symptomatic gout; results posted in 2011…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • KRYSTEXXA (pegloticase)

Snippet

Sponsor: Savient Pharmaceuticals | Conditions: Gout | Phase 3 | Status: COMPLETED | Results posted: 2011-02-25